Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 124 citing articles:

Interleukins in cancer: from biology to therapy
Daria Briukhovetska, Janina Dörr, Stefan Endres, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 8, pp. 481-499
Open Access | Times Cited: 549
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Katie L. Owen, Natasha K. Brockwell, Belinda S. Parker
Cancers (2019) Vol. 11, Iss. 12, pp. 2002-2002
Open Access | Times Cited: 537
Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy
Amrita Basu, Ganesan Ramamoorthi, Gabriella Albert, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 225
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
Laura Codarri, Valeria Nicolini, Masao Hashimoto, et al.
Nature (2022) Vol. 610, Iss. 7930, pp. 161-172
Open Access | Times Cited: 160
Engineering interferons and interleukins for cancer immunotherapy
Patrick G. Holder, Shion A. Lim, Christine Huang, et al.
Advanced Drug Delivery Reviews (2022) Vol. 182, pp. 114112-114112
Open Access | Times Cited: 96
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages
Mélanie Tichet, Stephan Wullschleger, Agnieszka Chryplewicz, et al.
Immunity (2023) Vol. 56, Iss. 1, pp. 162-179.e6
Open Access | Times Cited: 81
Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis
Miles Piper, Maureen Hoen, Laurel B. Darragh, et al.
Cancer Cell (2023) Vol. 41, Iss. 5, pp. 950-969.e6
Open Access | Times Cited: 48
Emerging biomaterials for tumor immunotherapy
Minna Xiao, Qinglai Tang, Shiying Zeng, et al.
Biomaterials Research (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 43
Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects
Barbara Bassani, Denisa Baci, Matteo Gallazzi, et al.
Cancers (2019) Vol. 11, Iss. 4, pp. 461-461
Open Access | Times Cited: 142
Targets and Antibody Formats for Immunotherapy of Neuroblastoma
Jeong A Park, Nai‐Kong V. Cheung
Journal of Clinical Oncology (2020) Vol. 38, Iss. 16, pp. 1836-1848
Open Access | Times Cited: 107
The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors
Denisa Baci, Annalisa Bosi, Matteo Gallazzi, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 9, pp. 3125-3125
Open Access | Times Cited: 103
Modulation of the tumor microenvironment (TME) by melatonin
Mu Qi, Masoud Najafi
European Journal of Pharmacology (2021) Vol. 907, pp. 174365-174365
Closed Access | Times Cited: 68
CD25: A potential tumor therapeutic target
Yujia Peng, Yiran Tao, Ya Zhang, et al.
International Journal of Cancer (2022) Vol. 152, Iss. 7, pp. 1290-1303
Closed Access | Times Cited: 49
Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives
Suheil Albert Atallah‐Yunes, Michael J. Robertson
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 47
Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies
Shan Muhammad, Tao Fan, Yang Hai, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 42
Profiling and targeting cancer stem cell signaling pathways for cancer therapeutics
Mia C. Borlongan, Hongbin Wang
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 24
Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies
Sahar Balkhi, Giorgia Bilato, Andrea De Lerma Barbaro, et al.
Vaccines (2025) Vol. 13, Iss. 1, pp. 69-69
Open Access | Times Cited: 1
Modulation of Signaling Mediated by TSLP and IL-7 in Inflammation, Autoimmune Diseases, and Cancer
Iva Marković, Savvas N. Savvides
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 60
Interleukin-2 therapy of cancer-clinical perspectives
Jamal Majidpoor, Keywan Mortezaee
International Immunopharmacology (2021) Vol. 98, pp. 107836-107836
Closed Access | Times Cited: 54
In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma
Isabella Lurje, Wiebke Werner, Raphael Mohr, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 46
Multifaceted Roles of Chemokines and Chemokine Receptors in Tumor Immunity
Kazuhiko Matsuo, Osamu Yoshie, Takashi Nakayama
Cancers (2021) Vol. 13, Iss. 23, pp. 6132-6132
Open Access | Times Cited: 45
Biobehavioral Pathways and Cancer Progression: Insights for Improving Well-Being and Cancer Outcomes
Aeson Chang, Erica K. Sloan, Michael H. Antoni, et al.
Integrative Cancer Therapies (2022) Vol. 21
Open Access | Times Cited: 33
Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection
Derek VanDyke, Marcos Iglesias, Jakub Tomala, et al.
Cell Reports (2022) Vol. 41, Iss. 3, pp. 111478-111478
Open Access | Times Cited: 32
Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies
Xinping Cao, Xin Jin, Xiaomei Zhang, et al.
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 3, pp. 184-211
Open Access | Times Cited: 19
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
Neeltje Steeghs, Carlos Gomez‐Roca, Kristoffer Rohrberg, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 13, pp. 2693-2701
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top